Kaiser Permanente Los Angeles Medical Center | Department of Research and Evaluation

Research site

(Unclaimed)

Location

4733 W. Sunset Boulevard 2nd Floor Suite 230, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Carboplatin

Paclitaxel

Bevacizumab

Cisplatin

Nivolumab

Temozolomide

Gemcitabine Hydrochloride

Docetaxel

Fluorouracil

Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

25 of 253 total trials

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) st...

Enrolling

Hypertension

Familial Primary Pulmonary Hypertension

Drug: Ralinepag

Drug: Placebo

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only

Hypertension

Familial Primary Pulmonary Hypertension

Drug: Ralinepag

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Biological: ExPEC9V

Other: Placebo

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting

COVID-19

Influenza

Biological: COVID-19 Vaccine

Biological: Investigational influenza vaccine

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling

High-risk Transient Ischemic Attack

Acute Non-cardioembolic Ischemic Stroke

Drug: Asundexian (BAY2433334)

Drug: Placebo

Amplatzer Amulet LAAO vs. NOAC (CATALYST)

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling

Atrial Fibrillation

Stroke

Drug: Non-Vitamin K Oral Antagonists

Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

AMPLATZER PFO Occluder Post Approval Study (PFO PAS)

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Enrolling

Stroke

Patent Foramen Ovale

Device: AMPLATZER™ PFO Occluder

AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE)

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN®...

Active, not recruiting

Stroke

Device: WATCHMAN Left Atrial Appendage Closure

Device: Amulet Left Atrial Appendage Occluder

Aveir DR i2i Study

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Lead...

Active, not recruiting

Bradycardia

Cardiac Rhythm Disorder

Device: Aveir DR Leadless Pacemaker System

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling

Stage III Colon Cancer

Drug: mFOLFOX6 3-6 month

Device: Signatera test

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lo...

Enrolling

Stroke

Intracranial Arteriosclerosis

Other: Risk Factor Management

Drug: Rivaroxaban + Aspirin

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting

Hormone-resistant Prostate Cancer

Stage IV Prostate Cancer

Drug: prednisone

Drug: abiraterone

Locations recently updated

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant...

Enrolling

Glioma

H3 K27M

Other: Placebo

Drug: Dordaviprone (ONC201) + Placebo

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting

Ovarian Neoplasms

Fallopian Tube Adenocarcinoma

Drug: Paclitaxel

Biological: Placebo

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Biological: Pembrolizumab

Biological: Ramucirumab

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute...

Enrolling

Intracerebral Hemorrhage

Biological: Recombinant Activated Factor VII (rFVIIa)

Biological: Placebo

S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting

Colorectal Neoplasms

Drug: Eflornithine placebo & sulindac placebo

Drug: Eflornithine plus sulindac

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab/rHuPH20

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Drug: PTM SEMA